Pharma. Shareholders Seek Almost $700M From SAC

May 15 2013 | 1:15pm ET

SAC Capital Advisors should pay Elan Corp. shareholders at least $685.6 million for losses suffered on the allegedly illegal trades made by the hedge fund in the pharmaceutical company's stock.

Elan shareholders, who first sued SAC in January, demanded at least $549.2 million in illicit profits in a consolidated complaint filed on Monday. The group, which is seeking class-action status, is also seeking $396 million in prejudgment interest. The disgorgement sought would be offset by $259.7 million from SAC's settlement with the Securities and Exchange Commission.

Elan is one of two companies that former SAC portfolio manager Mathew Martoma is alleged to have illegally traded while at the hedge fund. Martoma was charged in November with getting confidential information about Alzheimer's drug trials and using it to trade in Elan and Wyeth LLC shares, and has pleaded not guilty.

The would-be class action seeks to cover anyone who traded in Elan American depositary receipts or options from July 21 to 29, 2008.

Prosecutors have called the case against Martoma the "most lucrative" insider-trading scheme in history; they are reportedly seeking Martoma's cooperation in building a case against SAC founder Steven Cohen

In Depth

Financial Industry Blockchain Consortium R3 To Open-Source Platform Code

Oct 20 2016 | 9:03pm ET

Bitcoin's blockchain technology has spawned a flurry of activity among fintech startups...


U.S. Trust's Beard: The Rapid Growth of the Art Lending Industry

Oct 7 2016 | 10:55pm ET

Alternative investment managers have emerged as some of the most significant art...

Guest Contributor

Hedge Fund Marketing – Tips for Your Initial Sales Meeting

Sep 29 2016 | 5:46pm ET

There are two main goals a hedge fund should have for an initial in-person sales...